Biggest News Aggregation in the World
📰 Double Blind News

Page 12 - Double Blind News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Double Blind. Real-time updates on events, politics, business and more.

ProthioneTM Capsules Reduced Time to COVID-19 Clinical Resolution and Decreased Viral Load in Phase II Clinical Trial

Prothione capsules were safe and well tolerated Subjects with mild to moderate COVID-19 symptoms on Prothione experienced more rapid clinical resolution Patients with moderate to severe symptoms of COVID-19 on Prothione were 4 times less likely to be admitted to the hospital than those on placebo FRANKLIN, Tenn.--(BUSINESS WIRE)--Prothione LLC,…
United States Laura Lile Rinda Ubuzima Madeline James Rwanda Biomedical Centre Ministry Of Health

Innovent Announces Phase 2 study of MazdutideIBI362 in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints

SAN FRANCISCO and SUZHOU, China, June 8, 2022 /PRNewswire/ --Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announces that the primary and all key secondary endpoints were met in a randomized, double-blind, placebo-controlled phase 2 study of mazdutide (R&D code: IBI362), a glucagon-like...
United States Hong Kong Innovent Biologics Adimab Incyte Eli Lilly Linong Ji

Innovent Releases Results of High-dose Cohorts in Phase 1 Clinical Study of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity at ENDO 2022

SAN FRANCISCO and SUZHOU, China, June 13, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the results of high-dose cohorts in a phase 1 clinical trial of mazdutide (IBI362), a glucagon-like petide-1 (GLP-1) and glucagon receptor dual agonist, in...
United States Hong Kong Innovent Biologics Adimab Incyte Eli Lilly Linong Ji

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science